Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline

Biotech investors are probably a little depressed, with valuations of the industry down since their peak in February. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights explain why smaller development-stage companies have been hit especially hard during the downturn.